Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens.

Michaela Hložková,Jitka Malčíková,Nikola Tom,Marek Borsky,Yvona Brychtová,Michael Doubek,Anna Panovská,Eva Divíšková,Marek Mráz,Šárka Pospíšilová,Jiri Mayer,Martin Trbušek

Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens.

2017

Michaela Hložková
Jitka Malčíková
Nikola Tom
Marek Borsky
Yvona Brychtová
Michael Doubek
Anna Panovská
Eva Divíšková
Marek Mráz
Šárka Pospíšilová
Jiri Mayer
Martin Trbušek

Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens. Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens.

Keywords:

Front line
Rituximab
Progression-free survival
Cancer research
Medicine
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations